Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Topical LTX-109 for Nasal MRSA/MSSA Colonization
NCT01158235Phase 2Completed
- Sponsor
- Lytix Biopharma
- Start
- May 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of voxvoganan in Staphylococcus aureus colonization, sponsored by Lytix Biopharma. Started May 2010; status: completed.
02
Drugs
voxvoganan
03
Conditions
Staphylococcus aureus colonization
Beyond the preview
Go deeper on NCT01158235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01158235.